TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Multi-country, Open-label, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Who Are Not on Dialysis
Brief Summary: This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted over a period of up to 30 weeks.


Options:
A: Arm Label: GSK1278863 4 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 12 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 12 mg, GSK1278863 4 mg, GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Control
B: Arm Label: Darbepoetin Alfa Injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin Alfa Injection
C: Arm Label: 0.5 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 2 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 5 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: rhEPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): 0.5 mg GSK1278863, 2 mg GSK1278863, 5 mg GSK1278863 | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): rhEPO
D: Arm Label: AKB-6548; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Brief Summary: Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ipilimumab | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ipilimumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)
C: Arm Label: Neoadjuvant treatment + Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Neo treat with patho response-driven Adju treat or observation; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Adjuvant treatment, Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment
D: Arm Label: Arm A: Adjuvant Nivolumab (Complete Pathological Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm B: Adjuvant Nivolumab (Less than Complete Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm C: Adjuvant Combination (Less than Complete Response); Type: EXPERIMENTAL; Interventions: Drug: nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Arm A: Adjuvant Nivolumab (Complete Pathological Response), Arm B: Adjuvant Nivolumab (Less than Complete Response), Arm C: Adjuvant Combination (Less than Complete Response) | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm C: Adjuvant Combination (Less than Complete Response)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Dose, Open Label, Randomized, Cross-over Study in Participants With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94-9027 and Adynovi
Brief Summary: This study is being conducted to compare how the body distributes and excretes the drugs Jivi (BAY 94-9027) and Adynovi. Jivi is a recently approved blood clotting Factor VIII (FVIII) medication for the treatment of hemophilia A (bleeding disorder resulting from a lack of FVIII). Both drugs are FVIII products which have been manufactured via recombinant technology and have an extended half-live, i.e. they will stay longer in the body than other FVIII products. Therefore these products act longer in the body which reduces the frequency of drug injections. To compare the two drugs, a cross-over design was chosen, i.e. each patient will receive both products one after another.

Patients participating in this study will receive one dose of Jivi and one dose of Adynovi. Both drugs are injected into a vein. Observation will last for about 10 weeks, and blood samples will be taken from the participants to measure the blood levels of FVIII. Generic name of Jivi is Damoctocog-alfa-pegol, generic name of Adynovi is Rurioctocog alfa pegol.


Options:
A: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
B: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Concizumab, Placebo
C: Arm Label: Group 1; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Arm Label: Group 2; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 2
D: Arm Label: BAY94-9027 / Adynovi; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Arm Label: Adynovi / BAY94-9027; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Intervention Type: BIOLOGICAL; Name: Damoctocog-alfa-pegol (BAY94-9027, Jivi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi | Intervention Type: BIOLOGICAL; Name: Rurioctocog alfa pegol (Adynovi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison to Short-duration Tourniquet Total Knee Arthroplasty (TKA) With the Aquamantys® Bipolar Sealer and the Standard of Care in the Setting of Outpatient TKA: A Randomized, Double-blinded Study
Brief Summary: The purpose of this study is to compare quadriceps muscle strength, pain, opioid consumption and patient function during the first three months after short-stay total knee replacement between patients treated with short-duration tourniquet knee replacement with the Aquamantys® bipolar sealer versus those treated with the standard of care (tourniquet used throughout the case and no Aquamantys®).

By doing this study, investigators hope to learn if short duration tourniquet knee replacement with the Aquamantys® bipolar sealer is more effective than standard of care (tourniquet used throughout the case and no Aquamantys®). The purpose of this study is to compare quadriceps muscle strength, pain, opioid consumption and patient function during the first three months after short-stay total knee replacement between patients treated with short-duration tourniquet knee replacement with the Aquamantys® bipolar sealer versus those treated with the standard of care (tourniquet used throughout the case and no Aquamantys®).


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Neuraxial anesthesia | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): treatment | Intervention Type: DRUG; Name: Neuraxial anesthesia; Assigned to Arm(s): Placebo
B: Arm Label: Tourniquet; Type: EXPERIMENTAL; Interventions: Device: Tourniquet | Arm Label: No tourniquet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Tourniquet
C: Arm Label: tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Arm Label: non-tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Intervention Type: PROCEDURE; Name: Total knee arthroplasty; Assigned to Arm(s): non-tourniquet, tourniquet
D: Arm Label: Aquamantys; Type: EXPERIMENTAL; Interventions: Device: Aquamantys | Arm Label: Standard of Care: Tourniquet; Type: ACTIVE_COMPARATOR; Interventions: Device: Tourniquet | Intervention Type: DEVICE; Name: Aquamantys; Assigned to Arm(s): Aquamantys | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Standard of Care: Tourniquet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: A Prospective Double Blind Randomized Control Trial
Brief Summary: Patients presenting for normal spontaneous vaginal delivery who have a neuraxial anesthestic will be randomized to receive preservative free morphine or saline placebo after delivery.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule, Drug: Paracetamol | Arm Label: Ginger; Type: EXPERIMENTAL; Interventions: Drug: Ginger, Drug: Paracetamol | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Intervention Type: DRUG; Name: Ginger; Assigned to Arm(s): Ginger | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Ginger, Paracetamol, Placebo
B: Arm Label: Black tea bag; Type: EXPERIMENTAL; Interventions: Other: Warm water soaked Black Tea Bags | Arm Label: ice packs; Type: ACTIVE_COMPARATOR; Interventions: Other: Frozen perineal pad | Intervention Type: OTHER; Name: Frozen perineal pad; Assigned to Arm(s): ice packs | Intervention Type: OTHER; Name: Warm water soaked Black Tea Bags; Assigned to Arm(s): Black tea bag
C: Arm Label: Morphine; Type: EXPERIMENTAL; Interventions: Drug: Preservative Free Morphine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Preservative Free Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Other: Cold pads soaked in Magnesium sulfate solution | Arm Label: Water; Type: SHAM_COMPARATOR; Interventions: Other: Cold pads soaked in water | Intervention Type: OTHER; Name: Cold pads soaked in Magnesium sulfate solution; Assigned to Arm(s): Magnesium sulfate | Intervention Type: OTHER; Name: Cold pads soaked in water; Assigned to Arm(s): Water

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Randomized Clinical Trial in Subjects With Irritable Bowel Syndrome for the Identification of Gluten Sensitivity
Brief Summary: The aim of our study will be to establish in how many subjects with gastrointestinal symptoms and previous diagnosis of irritable bowel syndrome (IBS), the clinical picture is attributable to non celiac gluten sensitivity (NCGS) or fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) intolerance. For this purpose, all subjects with IBS will take a low FODMAPs diet, which implies the absence of cereals and consequently of gluten, and those presenting symptom improvement during this dietary treatment, will be exposed to a double-blind gluten or placebo challenge, to make a diagnosis of NCGS.


Options:
A: Intervention Type: OTHER; Name: Patients recruitment; Assigned to Arm(s): N/A
B: Arm Label: gluten-containing diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active comparator, gluten-free diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Gluten-free diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Gluten-free diet; Assigned to Arm(s): Active comparator, gluten-free diet
C: Arm Label: Gluten challenge; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Gluten challenge | Arm Label: Placebo challenge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo challenge | Intervention Type: DIETARY_SUPPLEMENT; Name: Gluten challenge; Assigned to Arm(s): Gluten challenge | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo challenge; Assigned to Arm(s): Placebo challenge
D: Arm Label: patients with IBS treated with gluten; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: diet containing gluten | Arm Label: patients with IBS treated with placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Diet containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: diet containing gluten; Assigned to Arm(s): patients with IBS treated with gluten | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet containing placebo; Assigned to Arm(s): patients with IBS treated with placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder
Brief Summary: A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).


Options:
A: Arm Label: A: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: B: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): A: Ketamine + Naltrexone or placebo, B: Ketamine + Naltrexone or placebo
B: Arm Label: Part 1: Block A MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block B MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block C MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block C Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block D MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block D Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: MK-8777 200 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: MK-8777 800 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MK-8777; Assigned to Arm(s): Part 1: Block A MK-8777, Part 1: Block B MK-8777, Part 1: Block C MK-8777, Part 1: Block D MK-8777, Part 2: MK-8777 200 mg, Part 2: MK-8777 800 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Block A Placebo, Part 1: Block B Placebo, Part 1: Block C Placebo, Part 1: Block D Placebo, Part 2: Placebo
C: Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AXS-05; Type: EXPERIMENTAL; Interventions: Drug: AXS-05 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AXS-05; Assigned to Arm(s): AXS-05 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder
Brief Summary: A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).


Options:
A: Arm Label: Omega-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA); Assigned to Arm(s): Omega-3, Placebo
B: Arm Label: AXS-05; Type: EXPERIMENTAL; Interventions: Drug: AXS-05 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AXS-05; Assigned to Arm(s): AXS-05 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
D: Arm Label: AZD6765 75 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: AZD6765 150 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Ketamine 0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 125 mL sterile NaCl 0.9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 75 mg | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 150 mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 125 mL sterile NaCl 0.9%

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Live-Online Mindfulness-based Intervention for Families of Children With Epilepsy: Making Mindfulness Matter© Randomized Control Trial
Brief Summary: Epilepsy is a debilitating condition characterized by spontaneous, unprovoked seizures. Up to 80% of children with epilepsy (CWE) may face cognitive, psychiatric, and/or behavioral comorbidities with significant unmet mental health needs. Mindfulness-based interventions may provide an ideal vector to target unmet mental healthcare needs in patients with epilepsy and their families. The investigators propose the Making Mindfulness Matter© (M3) program as an intervention to improve health related quality of life and mental-health for CWE and their parents. M3 is live-online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This pilot RCT is needed to refine the implementation of the intervention to families with a child with epilepsy, and collect information pertaining to the feasibility and effectiveness of the intervention in preparation for a subsequent multi-centred trial across Canada. Note: Due to COVID-19, the format has been modified for online delivery (from community-based) and the intervention has been restarted.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Making Mindfulness Matter© (M3) | Arm Label: Waitlist Control; Type: OTHER; Interventions: Behavioral: Making Mindfulness Matter© (M3) | Intervention Type: BEHAVIORAL; Name: Making Mindfulness Matter© (M3); Assigned to Arm(s): Intervention Group, Waitlist Control
B: Arm Label: AMOR Method; Type: EXPERIMENTAL; Interventions: Behavioral: The AMOR Method | Arm Label: Wait List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The AMOR Method; Assigned to Arm(s): AMOR Method
C: Arm Label: Care-as-usual (CAU) only; Type: OTHER; Interventions: Other: Care-as-usual for children (8-16 years old) with ADHD | Arm Label: Mindfulness for child and parent + CAU; Type: EXPERIMENTAL; Interventions: Other: MYmind mindfulness training, Other: Care-as-usual for children (8-16 years old) with ADHD | Intervention Type: OTHER; Name: MYmind mindfulness training; Assigned to Arm(s): Mindfulness for child and parent + CAU | Intervention Type: OTHER; Name: Care-as-usual for children (8-16 years old) with ADHD; Assigned to Arm(s): Care-as-usual (CAU) only, Mindfulness for child and parent + CAU
D: Arm Label: lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle counseling | Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling, Behavioral: Parenting Mindfully for Health (PMH) | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): lifestyle, therapy | Intervention Type: BEHAVIORAL; Name: Parenting Mindfully for Health (PMH); Assigned to Arm(s): therapy

Answer: A